End Stage Pulmonary Fibrosis Treatment Options

080115_Blog_InLineImagesPulmonary Fibrosis

Pulmonary fibrosis is a disease in which the lungs become scarred; this causes the complex passageways inside the lungs to thicken and harden. The hardening of passageways inside the lungs makes it difficult for oxygen to pass through the walls of the alveoli, which are tiny air sacs. This obstruction prevents oxygen from reaching the bloodstream. Lack of oxygen in the blood (hypoxemia) leaves sufferers of pulmonary fibrosis short of breath even after periods of prolonged rest. Pulmonary fibrosis is a progressive disease in which sufferers get worse over time, sometimes slowly and other times rapidly. Idiopathic pulmonary fibrosis means that the disease has no known cause. Pulmonary fibrosis is included in a family of conditions referred to as interstitial lung disease.

The Relationship of Pulmonary Fibrosis to Interstitial Lung Disease

Interstitial lung disease is an umbrella term used to identify a group of roughly 100 different types of pulmonary disorders that affect the absorption of oxygen in the lungs. All of these disorders alter the tissue and space (interstitium) surrounding the cluster-like air sacs (alveoli) of the lungs. The interstitium is not visible, but when an individual has interstitial lung disease, the interstitium becomes visible as a result of progressive scarring. This progressive scarring is characteristic of the entire family of disorders encompassed by interstitial lung disease such as pulmonary fibrosis. Previously the effects of interstitial lung disease were completely irreversible; now there are a variety of treatments available for individuals suffering from end stage interstitial lung disease.

End Stage Pulmonary Fibrosis Treatment Options

As suggested by the name end stage pulmonary fibrosis, the disease is not curable. However, it’s not untreatable. End stage pulmonary fibrosis is often referred to as stage four pulmonary fibrosis, which is the final stage of the disease, but there are still possible treatments despite the severity. In fact, there are many possible treatments for pulmonary fibrosis as there are a variety of possible causes and prognoses. As an incurable disease, the treatment is not meant to make the disease disappear, but rather can be used to improve a patient’s quality of life, to improve symptoms or to delay the progression of the disease. Initially, many physicians prescribe a combination of medicines to suppress the immune system, but these have not proved successful in the long run. In these situations, patients often progress to end stage pulmonary fibrosis. In order to help individuals struggling to breathe, supplemental oxygen can work to prevent shortness of breath and make life more comfortable. Occasionally, pulmonary rehabilitation and nutritional counseling are offered as a means of boosting a patient’s endurance. In the most severe cases, physicians may recommend a lung transplant, but this often has limited availability and extensive requirements for procedure eligibility. Thankfully, a new treatment using cells is available as a result of the hard work of a visionary group of physicians dedicated to improving the lives of individuals with lung disease.

Cells and Chronic Lung Disease

Cells are the building blocks of organisms. They have the ability for self-renewal and replication, thus are capable of forming any type of tissue or organ in the body. Adult cells from one organ are capable of forming tissue for another organ, which is called plasticity. It has been found that adult cells are capable of being transferred into any one single organ of the body.

Cellular Treatment for End Stage Pulmonary Fibrosis

In the case of people with end stage pulmonary fibrosis, autologous cells are used, meaning the cells come from the patient’s own body. They can be found in the patient’s bone marrow and blood (venous tissue). Cells derived from venous tissue have the capability to form many types of differentiated cells. During the procedure, adult cells are extracted from bone marrow or blood, which requires special laboratory techniques.

After extraction, the cells are isolated. Finally, they are returned to the patient intravenously. The treatment is minimally invasive and typically an outpatient procedure. The procedure should be performed in a clinical setting under the supervision of a professional. It takes a physician that has sought specific training to perform cellular therapy adequately and safely. If you would like to find out more about our available treatment options, please contact one of our patient care coordinators today at 888-745-6697 to schedule a free consultation.

*For more information, go to www.LungInstitute.com/Results.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.